%0 Journal Article
%T Unintended target effect of anti-BCL-2 DNAi
%A Abdul Shukkur Ebrahim
%A Amara B Sugalski
%A Ayad M Al-Katib
%A Leonard Lipovich
%A Mustapha Kandouz
%A Nada Emara
%J Archive of "Cancer Management and Research".
%D 2017
%R 10.2147/CMAR.S139105
%X Previous research suggested that a novel compound PNT2258 inhibits B-cell lymphoma 2 (BCL-2) transcription by DNA interference (DNAi) and demonstrated its activity in preclinical xenograft models and in a pilot Phase II clinical trial in non-Hodgkin¡¯s lymphoma (NHL). While the drug downregulates BCL-2 at the promoter, mRNA, and protein levels, there is a significant homology (13¨C16 bases) between PNT100 and a number of promoters of genes involved in cell cycle regulation and survival. In this study, we identify cyclin-dependent kinase-4 (CDK4) as an unintended target gene of PNT2258 and examine its relevance to NHL
%K non-Hodgkin¡¯s lymphoma
%K BCL-2
%K PNT2258
%K BLAST
%K CDK4
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624602/